UK approval for Gilead HIV drug with blockbuster potential

26 August 2022

The UK’s Medicines and Healthcare Regulatory Agency (MHRA) has approved Sunlenca (lenacapavir) injection and tablets, in combination with other antiretrovirals, in adults with multi-drug resistant HIV infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen.

Gilead Sciences’ (Nasdaq: GILD) therapy is a first-in-class capsid inhibitor with a multi-stage mechanism of action that has no known cross resistance to other existing drug classes, offering a new, every six-month treatment option for eligible adults with HIV whose virus no longer effectively responds to their current therapy.

"Lenacapavir will now be the first twice-yearly treatment for people who struggle with multi-drug resistant HIV"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK